Genmab — Februar 2019
-
God morgen.

-
I med- og modgang... gode gamle Roger rammer altid plet

-
Op med humøret
https://youtu.be/LY5RRsoUrcY -
Johnson & Johnson har fået en orphan medicinalstatus hos de amerikanske
sundhedsmyndigheder (FDA) til en behandling af knoglemarvskræft (multipel myeloma) til en T-celle-behandling mod B-celle maturation antigen (BCMA) proteinmål. Genmab har udviklet Darzalex, der også er en behandling mod knoglemarvskræft. Orphan medicinalstatus giver syv års markedseksklusivitet, hvis den bliver godkendt af FDA mod sjældne sygdomme. Kilde: Aktiefokus 4/2. -
-
Her kan man se nogle af de berømte infusionsstole http://www.mattvsmyeloma.com/2019/02/cruise-control-redux.html
-
-
Ved ikke om denne har været vist. Dara i Ph 4 starter 15 marts. https://clinicaltrials.gov/ct2/show/NCT03768960?term=darzalex&cond=Multiple+Myeloma&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
